Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 30% ± 4% | |
ciliated cell | 3 studies | 18% ± 2% | |
endothelial cell | 3 studies | 18% ± 3% |
Insufficient scRNA-seq data for expression of ELOA at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2866.33 | 1445 / 1445 | 100% | 41.82 | 183 / 183 |
liver | 100% | 2528.15 | 226 / 226 | 100% | 22.24 | 406 / 406 |
lung | 100% | 3435.22 | 578 / 578 | 100% | 40.74 | 1155 / 1155 |
ovary | 100% | 2662.87 | 180 / 180 | 100% | 29.31 | 430 / 430 |
pancreas | 100% | 2464.10 | 328 / 328 | 100% | 29.82 | 178 / 178 |
prostate | 100% | 2664.02 | 245 / 245 | 100% | 39.79 | 502 / 502 |
skin | 100% | 3788.00 | 1809 / 1809 | 100% | 49.72 | 472 / 472 |
stomach | 100% | 3838.72 | 359 / 359 | 100% | 28.04 | 286 / 286 |
breast | 100% | 3072.16 | 459 / 459 | 100% | 38.66 | 1117 / 1118 |
bladder | 100% | 2641.81 | 21 / 21 | 100% | 36.05 | 503 / 504 |
uterus | 100% | 2619.99 | 170 / 170 | 100% | 39.71 | 458 / 459 |
thymus | 100% | 2830.12 | 653 / 653 | 100% | 33.80 | 603 / 605 |
intestine | 100% | 2473.81 | 966 / 966 | 99% | 26.93 | 524 / 527 |
brain | 99% | 1517.73 | 2625 / 2642 | 100% | 31.68 | 705 / 705 |
kidney | 100% | 1994.31 | 89 / 89 | 98% | 21.03 | 884 / 901 |
adrenal gland | 100% | 2289.08 | 258 / 258 | 95% | 18.08 | 218 / 230 |
adipose | 100% | 3334.00 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2185.43 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 34.06 | 29 / 29 |
muscle | 100% | 2829.57 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2849.90 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 36.54 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.74 | 1 / 1 |
heart | 98% | 1637.92 | 844 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 26.20 | 78 / 80 |
peripheral blood | 87% | 1584.80 | 811 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006368 | Biological process | transcription elongation by RNA polymerase II |
GO_0006367 | Biological process | transcription initiation at RNA polymerase II promoter |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0005615 | Cellular component | extracellular space |
GO_0090734 | Cellular component | site of DNA damage |
GO_0070449 | Cellular component | elongin complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005515 | Molecular function | protein binding |
Gene name | ELOA |
Protein name | Elongin-A (EloA) (Elongin 110 kDa subunit) (RNA polymerase II transcription factor SIII subunit A1) (SIII p110) (Transcription elongation factor B polypeptide 3) |
Synonyms | MSTP059 TCEB3 |
Description | FUNCTION: SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A is transcriptionally active and its transcription activity is strongly enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C (elongin BC complex). .; FUNCTION: As part of a multisubunit complex composed of elongin BC complex (ELOB and ELOC), elongin A/ELOA, RBX1 and CUL5; polyubiquitinates monoubiquitinated POLR2A. . |
Accessions | ENST00000613537.5 [Q14241-2] Q14241 |